Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||- / 1||- / -|
Administered by: Unknown Purchased by: ??
Symptoms: Chest pain, Dyspnoea, Electrocardiogram, Feeling abnormal, Myocarditis
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Diagnostic Lab Data: Test Name: EKG; Result Unstructured Data: Test Result:Abnormal; Comments: received an EKG that was abnormal
CDC 'Split Type': USPFIZER INC202101169446
Write-up: Caller thinks it is Myocarditis.; Chest pain; Shortness of breath; felt like her lungs couldn''t fill up; This is a spontaneous report from a contactable Nurse (patient) A 41-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number not provided), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunisation. Relevant medical history and concomitant medications were not reported. Immediately after receiving the vaccine patient began having chest pain, shortness of breath and felt like her lungs couldn''t fill up. She has not gotten better in two weeks. She thought it sounds like Myocarditis (as reported). The patient went to urgent care center, they told her not to go to the Emergency Room for risk of getting Covid.Stated they did an office EKG and said they would send it to cardiologist. (as reported). The patient underwent lab tests and procedures which included electrocardiogram abnormal on an unspecified date. At the time of the reporting the patient had not yet recovered from chest pain and Shortness of breath, outcome of other reported events was unknown.; Sender''s Comments: Based on the information currently available, a possible contributory role of the suspect drug in the reported serious event Myocarditis cannot be completely ruled out given the known suspect drug profile and/or implied temporal association. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regul atory Authorities, Ethics Committees and Investigators, as appropriate
Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166